Literature DB >> 12624096

The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.

Patricia M-J Lievens1, Elio Liboi.   

Abstract

The K650E substitution in the fibroblast growth factor receptor 3 (FGFR3) causes constitutive tyrosine kinase activity of the receptor and is associated to the lethal skeletal disorder, thanatophoric dysplasia type II (TDII). The underlying mechanisms of how the activated FGFR3 causes TDII remains to be elucidated. FGFR3 is a transmembrane glycoprotein, which is synthesized through three isoforms, with various degrees of N-glycosylation. We have studied whether immature FGFR3 isoforms mediate the abnormal signaling in TDII. We show that synthesis of TDII-FGFR3 presents two phosphorylated forms: the immature non-glycosylated 98-kDa peptides and the intermediate 120-kDa glycomers. The mature, fully glycosylated 130-kDa forms, detected in wild type FGFR3, are not present in TDII. Endoglycosidase H cleaves the sugars on TDII intermediates thus indicating their intracellular localization in the endoplasmic reticulum. Accordingly, TDII-FGFR3-GFP co-localizes with calreticulin in the endoplasmic reticulum. Furthermore, following TDII transfection, signal transducer and activator of transcription 1 (STAT1) is phosphorylated in the absence of FGFR3 ligand and brefeldin A does not inhibit its activation. On the contrary, the cell membrane-anchored FRS2alpha protein is not activated in TDII cells. The opposite situation is observed in stable TDII cell clones where, despite the presence of phosphorylated mature receptor, STAT1 is not activated whereas FRS2alpha is phosphorylated. We speculate that the selection process favors cells defective in STAT1 activation through the 120-kDa TDII-FGFR3, thus allowing growth of the TDII cell clones. Accordingly, apoptosis is observed following TDII-FGFR3 transfection. These observations highlight the importance of the immature TDII-FGFR3 proteins as mediators of an abnormal signaling in TDII.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12624096     DOI: 10.1074/jbc.M212710200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

2.  Precursor B cell receptor signaling activity can be uncoupled from surface expression.

Authors:  F Betul Guloglu; Christopher A J Roman
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

Review 3.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

4.  Thanatophoric dysplasia. Correlation among bone X-ray morphometry, histopathology, and gene analysis.

Authors:  Ugo E Pazzaglia; Carla M Donzelli; Claudia Izzi; Maurizia Baldi; Giuseppe Di Gaetano; MariaPia Bondioni
Journal:  Skeletal Radiol       Date:  2014-05-25       Impact factor: 2.199

5.  Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Authors:  April N Meyer; Christopher W McAndrew; Daniel J Donoghue
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

6.  ZDHHC3 Tyrosine Phosphorylation Regulates Neural Cell Adhesion Molecule Palmitoylation.

Authors:  Patricia Marie-Jeanne Lievens; Tatiana Kuznetsova; Gaga Kochlamazashvili; Fabrizia Cesca; Natalya Gorinski; Dalia Abdel Galil; Volodimir Cherkas; Natalia Ronkina; Juri Lafera; Matthias Gaestel; Evgeni Ponimaskin; Alexander Dityatev
Journal:  Mol Cell Biol       Date:  2016-08-12       Impact factor: 4.272

Review 7.  Achondroplasia: Development, pathogenesis, and therapy.

Authors:  David M Ornitz; Laurence Legeai-Mallet
Journal:  Dev Dyn       Date:  2017-03-02       Impact factor: 3.780

8.  Differential regulation of FGFR3 by PTPN1 and PTPN2.

Authors:  Jonathan R St-Germain; Paul Taylor; Wen Zhang; Zhihua Li; Troy Ketela; Jason Moffat; Benjamin G Neel; Suzanne Trudel; Michael F Moran
Journal:  Proteomics       Date:  2014-12-17       Impact factor: 3.984

9.  Comparative X-ray morphometry of prenatal osteogenesis imperfecta type 2 and thanatophoric dysplasia: a contribution to prenatal differential diagnosis.

Authors:  Maria Pia Bondioni; Ugo Ernesto Pazzaglia; Claudia Izzi; Giuseppe Di Gaetano; Francesco Laffranchi; Maurizia Baldi; Federico Prefumo
Journal:  Radiol Med       Date:  2017-07-03       Impact factor: 3.469

10.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.